Although all three phase III trials evaluating EGFR inhibition in mEGC failed to achieve their primary endpoints, EGFR biomarker analysis suggests that as in lung and colon cancers, EGFR inhibition has a significant role in a properly selected population. The gene discussed is EGFR; the disease is malignant colon neoplasm.